---
figid: PMC8158155__fendo-12-635995-g002
figtitle: Ceramides and Sphingosino-1-Phosphate in Obesity
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC8158155
filename: fendo-12-635995-g002.jpg
figlink: /pmc/articles/PMC8158155/figure/f2/
number: F2
caption: Metabolic effect of S1P in adipocyte. (A) S1P inhibits adipogenesis by affecting
  the expression of transcriptional factor PPARγ (); (B) S1P reduces the anti-inflammatory
  response (IL-10) and adiponectin synthesis which is accompanied by (E) an increased
  proinflammatory cytokine levels (IL-6, TNFα) lead to the activation of PP2A leaving
  Akt dephosphorylated and inactive (); (C) In cAMP/PKA dependent pathway S1P stimulates
  lipolysis and inhibits insulin-mediated leptin synthesis (); (D) S1P intensifies
  TLR4 activation cause impaired insulin signalling via IKK- NF-κB axis (); (F) S1P
  stimulates secretion of chemokine MCP-1 leads to increased macrophage migration
  (); (+) activation, (-) inhibition, TNFα -tumor necrosis factor, IL-6, interleukin
  6; IL-10, interleukin 10; Act, protein kinase 3; TLR4, Toll like receptor 4; IKK,
  inhibitor kappa kinase; NF-κB, nuclear factor κB; PKA, protein kinase A; PPARγ,
  peroxisome proliferator-activated receptor gamma; MCP-1, monocyte chemoattractant
  protein-1.
papertitle: Ceramides and Sphingosino-1-Phosphate in Obesity.
reftext: Ilona Juchnicka, et al. Front Endocrinol (Lausanne). 2021;12:635995.
year: '2021'
doi: 10.3389/fendo.2021.635995
journal_title: Frontiers in Endocrinology
journal_nlm_ta: Front Endocrinol (Lausanne)
publisher_name: Frontiers Media S.A.
keywords: ceramides | sphingolipids | S1P | obesity | adipose tissue
automl_pathway: 0.9307886
figid_alias: PMC8158155__F2
figtype: Figure
redirect_from: /figures/PMC8158155__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8158155__fendo-12-635995-g002.html
  '@type': Dataset
  description: Metabolic effect of S1P in adipocyte. (A) S1P inhibits adipogenesis
    by affecting the expression of transcriptional factor PPARγ (); (B) S1P reduces
    the anti-inflammatory response (IL-10) and adiponectin synthesis which is accompanied
    by (E) an increased proinflammatory cytokine levels (IL-6, TNFα) lead to the activation
    of PP2A leaving Akt dephosphorylated and inactive (); (C) In cAMP/PKA dependent
    pathway S1P stimulates lipolysis and inhibits insulin-mediated leptin synthesis
    (); (D) S1P intensifies TLR4 activation cause impaired insulin signalling via
    IKK- NF-κB axis (); (F) S1P stimulates secretion of chemokine MCP-1 leads to increased
    macrophage migration (); (+) activation, (-) inhibition, TNFα -tumor necrosis
    factor, IL-6, interleukin 6; IL-10, interleukin 10; Act, protein kinase 3; TLR4,
    Toll like receptor 4; IKK, inhibitor kappa kinase; NF-κB, nuclear factor κB; PKA,
    protein kinase A; PPARγ, peroxisome proliferator-activated receptor gamma; MCP-1,
    monocyte chemoattractant protein-1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - il10
  - mbtps1
  - il6
  - tnfa
  - tnfb
  - CCL2
  - IL10
  - MBTPS1
  - IL6
  - TNF
  - SERPINA3
  - ACTG1
  - ACTG2
  - FHL5
  - ACOT7
  - ACTBL2
  - POTEKP
  - POTEM
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - TLR4
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - NFKB1
---
